KLRC1 and non-small cell lung carcinoma: Monalizumab (IPH2201), jointly developed by Innate Pharma and AstraZeneca, is an NKG2A monoclonal antagonistic antibody that can block the interaction between NKG2A and HLA-E and has shown therapeutic effects in a leukemia mouse model.250 Monalizumab has been used in phase II clinical trials against cancers of the female reproductive system and NSCLC.251 In these clinical studies, monalizumab was well tolerated but with limited therapeutic effect, and only showed short-term SD in some patients.